Cancer Biomarkers Market By Product 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Cancer Biomarkers Market
Cancer Biomarkers Market: By Product (ELISA Pair Sets, RNA, Tumor Suppressor, cDNA Clone, Others) Type (Protein, Genetic, Others) Technology (Immunoassays, Cytogenetics, Others) Tumor Type (Cervical, Prostate, Others) Application (Diagnostics, Others)-Forecast (2017-2022)
Report Code : HCR 0194
Updated Date: 25 February, 2016  

  • Report Description
  • Table of Contents
  • Customization Options
1. Cancer Biomarkers Market Overview
2. Executive Summary
3. Cancer Biomarkers Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
   3.3. Product Benchmarking
   3.4. End User Profiling
   3.5. Top 5 Financials Analysis
4. Cancer Biomarkers Market Forces
   4.1. Drivers
      4.1.1. Rising incidences of cancer
      4.1.2. Growing research on cancer biomarkers
      4.1.3. Superior speed and accuracy of diagnosis
   4.2. Restraints
      4.2.1. Higher capital investments
      4.2.2. Lack of reimbursement and regulatory systems
      4.2.3. Technical issues
   4.3. Opportunities
      4.3.1. Developing countries
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Cancer Biomarkers Market, By Product
   5.1. ELISA pair sets based
   5.2. RNA based
   5.3. Tumor suppressor based
   5.4. cDNA clone based
   5.5. Others
6. Cancer Biomarkers Market, By Type
   6.1. Protein Biomarkers
   6.2. Genetic Biomarkers
   6.3. Others
7. Cancer Biomarkers Market, By Tumor Type
   7.1. Colorectal Cancer
   7.2. Cervical Cancer
   7.3. Lung Cancer
   7.4. Prostate Cancer
   7.5. Breast Cancer
   7.6. Others
8. Cancer Biomarkers Market, By Technology
   8.1. Immunoassays
   8.2. Omics Technologies
   8.3. Cytogenetics
   8.4. Imaging Technologies
   8.5. Bioinformatics
9. Cancer Biomarkers Market, By Application
   9.1. Drug Discovery and Development
   9.2. Diagnostics
   9.3. Risk Assessment
   9.4. Prognostics
   9.5. Others
10. Cancer Biomarkers Market, By Geography
   10.1. Europe
      10.1.1. Germany
      10.1.2. France
      10.1.3. Italy
      10.1.4. Spain
      10.1.5. Russia
      10.1.6. U.K.
      10.1.7. Rest of Europe
   10.2. Asia Pacific
      10.2.1. China
      10.2.2. India
      10.2.3. Japan
      10.2.4. South Korea
      10.2.5. Rest of Asia-Pacific
   10.3. North America
      10.3.1. U.S.
      10.3.2. Canada
      10.3.3. Mexico
   10.4. Rest of the World (RoW)
      10.4.1. Brazil
      10.4.2. Rest of RoW
11. Cancer Biomarkers – Market Entropy
   11.1. Expansion
   11.2. Technological Developments
   11.3. Merger & Acquisitions, and Joint Ventures
   11.4. Supply- Contract
12. Company Profiles
   12.1. Abbott Laboratories
      12.1.1. Introduction
      12.1.2. Financials
      12.1.3. Key Insights
      12.1.4. Key Strategy
      12.1.5. Product Portfolio
      12.1.6. SWOT Analysis
   12.2. Affymetrix, Inc.
      12.2.1. Introduction
      12.2.2. Financials
      12.2.3. Key Insights
      12.2.4. Key Strategy
      12.2.5. Product Portfolio
      12.2.6. SWOT Analysis
   12.3. Illumina, Inc.
      12.3.1. Introduction
      12.3.2. Financials
      12.3.3. Key Insights
      12.3.4. Key Strategy
      12.3.5. Product Portfolio
      12.3.6. SWOT Analysis
   12.4. Qiagen N.V.
      12.4.1. Introduction
      12.4.2. Financials
      12.4.3. Key Insights
      12.4.4. Key Strategy
      12.4.5. Product Portfolio
      12.4.6. SWOT Analysis
   12.5. Roche Diagnostics Ltd.
      12.5.1. Introduction
      12.5.2. Financials
      12.5.3. Key Insights
      12.5.4. Key Strategy
      12.5.5. Product Portfolio
      12.5.6. SWOT Analysis
   12.6. Agilent Technologies, Inc.
      12.6.1. Introduction
      12.6.2. Financials
      12.6.3. Key Insights
      12.6.4. Key Strategy
      12.6.5. Product Portfolio
      12.6.6. SWOT Analysis
   12.7. Quest Diagnostics Inc.
      12.7.1. Introduction
      12.7.2. Financials
      12.7.3. Key Insights
      12.7.4. Key Strategy
      12.7.5. Product Portfolio
      12.7.6. SWOT Analysis
   12.8. Merck & Co. Inc.
      12.8.1. Introduction
      12.8.2. Financials
      12.8.3. Key Insights
      12.8.4. Key Strategy
      12.8.5. Product Portfolio
      12.8.6. SWOT Analysis
   12.9. Hologic, Inc.
      12.9.1. Introduction
      12.9.2. Financials
      12.9.3. Key Insights
      12.9.4. Key Strategy
      12.9.5. Product Portfolio
      12.9.6. SWOT Analysis
   12.10. Becton, Dickinson and Company
      12.10.1. Introduction
      12.10.2. Financials
      12.10.3. Key Insights
      12.10.4. Key Strategy
      12.10.5. Product Portfolio
      12.10.6. SWOT Analysis
*More than 10 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
13. Appendix
   13.1. Abbreviations
   13.2. Sources
   13.3. Research Methodology
   13.4. Bibliography
   13.5. Compilation of Expert Insights
   13.6. Disclaimer
Cancer biomarkers are biological molecule found in blood, other body fluids, or tissues and are indicative of the presence of cancer in the body. Cancer biomarkers improves the cancer detection and facilitate high speed, non-invasive diagnosis using genomics and proteomics based tools. Globally, rising incidences of cancer, growing research on cancer biomarkers, and superior speed and accuracy of diagnosis are the prime growth drivers of cancer biomarkers market. In addition, emerging economies such as China, India and others will create new opportunities for cancer biomarkers market. However, higher capital investments, lack of reimbursement, and regulatory systems, and technical issues are the key restraints for cancer biomarkers market.

This report identifies the global cancer biomarkers market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to global cancer biomarkers market.
Cancer Biomarkers Market

Geographically North America dominated cancer biomarkers market, followed by Europe due to growing government support for discovery and development of biomarkers, and rising usage of advanced omics technologies for the biomarker discovery. Asia Pacific is projected to have fastest growth, owing to rising incidences of cancer, and expansions by key market players in this region. Among all the applications, diagnostics segment has the highest market share in cancer biomarkers market followed by drug discovery and development.

This report segments cancer biomarkers market on the basis of product, technology, application, end-user, and regional market as follows:
  • Cancer Biomarkers Market, By Product: ELISA pair sets based, RNA based, Tumor suppressor based, cDNA clone based, and Others
  • Cancer Biomarkers Market, By Type: Protein Biomarkers, Genetic Biomarkers, and Others
  • Cancer Biomarkers Market, By Tumor Type: Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer, Breast Cancer, and Others
  • Cancer Biomarkers Market, By Technology: Immunoassays, Omics Technologies, Cytogenetics, Imaging Technologies, and Bioinformatics
  • Cancer Biomarkers Market, By Application: Drug Discovery and Development, Diagnostics, Risk Assessment, Prognostics, and Others
  • This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region

Sample Companies Profiled in this Report are:
  • Abbott Laboratories
  • Affymetrix, Inc.
  • Illumina, Inc.
  • Qiagen N.V.
  • Roche Diagnostics Ltd.
  • 10+.
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports